Literature DB >> 21302636

The ENETS guidelines: the new TNM classification system.

Guido Rindi1.   

Abstract

The WHO definition of the 3 classes of well differentiated endocrine tumor, well differentiated endocrine carcinoma and poorly differentiated carcinoma, allows an efficient general classification of GEP NETs fitting European Union (EU) current clinical use. The ENETS grading and TNM staging systems are complementary tools allowing to improve patients' stratification, and their adoption is strongly recommended. However, the prognostic value of these tools is still under investigation and more data are needed to support their usefulness at all gut sites and in perspective series. Similarly, the four classes system adopted by the WHO for the endocrine tumors of the lung allows a prognostically effective stratification of patients. A common grading system is advocated for lung and GEP NETS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21302636     DOI: 10.1177/030089161009600532

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  37 in total

1.  Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?

Authors:  Fumihito Toshima; Dai Inoue; Takahiro Komori; Kotaro Yoshida; Norihide Yoneda; Tetsuya Minami; Osamu Matsui; Hiroko Ikeda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2017-03-03       Impact factor: 2.374

Review 2.  Calcified liver metastases from a non-functioning pancreatic neuroendocrine tumor.

Authors:  Terufumi Kawamoto; Tsunekazu Hishima; Kiminori Kimura
Journal:  Clin J Gastroenterol       Date:  2014-08-29

3.  A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram.

Authors:  Trevor A Ellison; Christopher L Wolfgang; Chanjuan Shi; John L Cameron; Peter Murakami; Liew Jun Mun; Aatur D Singhi; Toby C Cornish; Kelly Olino; Zina Meriden; Michael Choti; Luis A Diaz; Timothy M Pawlik; Richard D Schulick; Ralph H Hruban; Barish H Edil
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

4.  Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.

Authors:  Samer Ezziddin; Feras Khalaf; Maria Vanezi; Torjan Haslerud; Karin Mayer; Abdullah Al Zreiqat; Winfried Willinek; Hans-Jürgen Biersack; Amir Sabet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-07       Impact factor: 9.236

5.  Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.

Authors:  Amir Sabet; Alexander R Haug; Collin Eiden; Christoph J Auernhammer; Birgit Simon; Peter Bartenstein; Hans J Biersack; Samer Ezziddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-04-15

Review 6.  Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.

Authors:  Sven-Petter Haugvik; Daniel Kaemmerer; Sebastien Gaujoux; Knut Jørgen Labori; Caroline Sophie Verbeke; Ivar Prydz Gladhaug
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

Review 7.  Consensus on biomarkers for neuroendocrine tumour disease.

Authors:  Kjell Oberg; Irvin M Modlin; Wouter De Herder; Marianne Pavel; David Klimstra; Andrea Frilling; David C Metz; Anthony Heaney; Dik Kwekkeboom; Jonathan Strosberg; Timothy Meyer; Steven F Moss; Kay Washington; Edward Wolin; Eric Liu; James Goldenring
Journal:  Lancet Oncol       Date:  2015-09       Impact factor: 41.316

8.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

9.  Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

Authors:  Stefano Severi; Oriana Nanni; Lisa Bodei; Maddalena Sansovini; Annarita Ianniello; Stefania Nicoletti; Emanuela Scarpi; Federica Matteucci; Laura Gilardi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-27       Impact factor: 9.236

10.  Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.

Authors:  Dong Wook Kim; Hyoung Jung Kim; Kyung Won Kim; Jae Ho Byun; So Yeon Kim; Ki Byung Song; Nikhil H Ramaiya; Sree Harsha Tirumani; Seung-Mo Hong
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.